Innovating and Delivering New Technologies

Cordis is proud to have completed the acquisition of MedAlliance and its novel SELUTION SLR™ Drug-Eluting Balloon (DEB). Using breakthrough proprietary technology, MedAlliance has found a unique solution to the challenge of controlled and sustained sirolimus release with the SELUTION SLR DEB. Cordis and MedAlliance combined are committed to accelerating the development and commercialization of innovative cardiovascular interventional products around the world.

The SELUTION SLR Drug-Eluting Balloon is not approved for sale in every country. Please contact your local representative for additional information

Driven by mission, guided by values

Cordis is making a difference. We impact millions of lives, in more than 60 countries around the world. We embrace a diverse, empowered culture where teammates are inspired to serve customers, patients and shareholders while fulfilling their own career aspirations.


Cordis: Imagine This.

At the center of our passion for advancing cardiovascular and endovascular health are the clinicians and collaborators on the frontlines. They inspire us each and every day with their commitment to continuously move the needle. As we celebrate one year of independence, we are even more proud than we were 62 years ago to stand behind the heroes that allow us all to be truly free at heart.

Need Help?

We’re here with the support and information to help you make the right choices for your patients.